40	Phase II clinical trial to study the safety and efficacy of combined S‑1 + oxaliplatin therapy as neoadjuvant chemotherapy for locally advanced gastric cancer in older patients Ota M, Saeki H, Uehara H, Matsuda Y, Tsutsumi T, Kusumoto T, Yasui H, Ubukata Y, Yamaguchi S, Orita H, Izawa N, Kakizoe S, Shimokawa M, Yoshizumi T, Kakeji Y, Mori M, Oki E Int J Clin Oncol. 2023 Sep;28(9):1166-1175.
39	Genomic characterization between HER2-positive and negative gastric cancer patients in a prospective trial Hu Q, Oki E, Yamada T, Kashiwada T, Sonoda H, Kataoka M, Kawanaka H, Tsuji Y, Makiyama A, Nakashima Y, Ota M, Kimura Y, Yoshizumi T Cancer Med 2023 Aug;12(15):16649-16660
38	Immune checkpoint status and oncogenic mutation profiling of rectal cancer after neoadjuvant chemotherapy (KSCC1301-A2) Miyashita Y, Oki E, Kamori T, Akagi T, Mori S, Hattori N, Kobayashi K, Shimokawa M, Oda Y, Mori M Ann Gastroenterol Surg 21 August 2023 https://doi.org/10.1002/ags3.12730
37	A phase II multicenter trial assessing the efficacy and safety of first-line S-1 + ramucirumab in elderly patients with advanced/recurrent gastric cancer: KSCC1701 Kazuma Kobayshi , Koichi Suyama , Hiroo Katsuya , Naoki Izawa , Yoshikazu Uenosono , Qingjiang Hu , Tetsuya Kusumoto , Hajime Otsu , Hiroyuki Orita , Hirofumi Kawanaka , Kazunori Shibao , Satoshi Koga , Mototsugu Shimokawa , Akitaka Makiyama , Hiroshi Saeki , Eiji Oki , Hideo Baba , Masaki Mori , KSCC1701 study group European Journal of Cancer. 2022 Mar 26;166:279-286. doi: 10.1016/j.ejca.2022.02.028. Online ahead of print.
36	Phase II study of S-1 and oxaliplatin as neoadjuvant chemotherapy for locally advanced adenocarcinoma of the gastric or esophagogastric junction: KSCC1601 Masaaki Iwatsuki , Hiroyuki Orita , Kazuma Kobayashi , Shigekazu Hidaka , Takaaki Arigami , Tetsuya Kusumoto , Hironaga Satake , Eiji Oki , Satoshi Tsutsumi , Kazutoshi Tobimatsu , Mototsugu Shimokawa , Hiroshi Saeki , Akitaka Makiyama , Hideo Baba , Masaki Mori Gastric Cancer. 2021 Aug 11. doi: 10.1007/s10120-021-01218-0. Online ahead of print.
35	Monitoring FTD in the peripheral blood mononuclear cells of elderly patients with metastatic colorectal cancer administered FTD plus bevacizumab as first-line treatment Yoshiaki Fujimoto, Eiji Oki, Shichao Qiu, Ryota Nakanishi, Akitaka Makiyama, Yuji Miyamoto, Masahito Kotaka, Mototsugu Shimokawa, Koji Ando, Yasue Kimura, Hiroyuki Kitao, Yoshihiko Maehara, Masaki Mori Cancer Sci. 2021 Mar 29. doi: 10.1111/cas.14904. Online ahead of print.
34	Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301) Keisuke Miwa, Eiji Oki, Masanobu Enomoto, Keisuke Ihara, Koji Ando, Fumihiko Fujita, Masahiro Tominaga, Shinichiro Mori, Goro Nakayama, Mototsugu Shimokawa, Hiroshi Saeki, Hideo Baba, Masaki Mori, Yoshito Akagi BMC Cancer. 2021 Jan 5;21(1):23. doi: 10.1186/s12885-020-07766-5.
33	Trifluridine/tipiracil plus bevacizumab as a first-line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial. Oki E, Makiyama A, Miyamoto Y, Kotaka M, Kawanaka H, Miwa K, Kabashima A, Noguchi T, Yuge K, Kashiwada T, Ando K, Shimokawa M, Saeki H, Akagi Y, Baba H, Maehara Y, Mori M. Cancer Med. 2020 Nov 29. doi: 10.1002/cam4.3618. Online ahead of print.
32	Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer Hironaga Satake, Koji Ando, Eiji Oki, Mototsugu Shimokawa, Akitaka Makiyama, Hiroshi Saeki, Akihito Tsuji, Masaki Mori BMC Cancer. 2020 Nov 17;20(1):1116. doi: 10.1186/s12885-020-07576-9.
31	Safety and efficacy of S-1 plus oxaliplatin 130 mg/m(2) combination therapy in patients with previously untreated HER2-negative unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: a phase II trial (KSCC1501A). Kashiwada T, Shinozaki K, Ueno S, Kawanaka H, Uno F, Okita Y, Fukahori M, Matsushita H, Emi Y, Shimokawa M, Makiyama A, Saeki H, Oki E, Maehara Y, Mori M, Baba E; Kyushu Study Group of Clinical Cancer (KSCC). Int J Clin Oncol. 2020 Oct 21. doi: 10.1007/s10147-020-01803-w. Online ahead of print.
30	A phase I/II study of S-1 and irinotecan (IRIS) combined with cetuximab in patients with RAS wild-type metastatic colorectal cancer (KSCC1401) Hironori Samura, Eiji Oki, Hiroshi Okumura, Takefumi Yoshida, Seiichiro Kai, Kazuma Kobayashi, Tatsuya Kinjo, Shinichiro Mori, Tetsuo Tohyama, Kippei Ohgaki, Hirofumi Kawanaka, Akitaka Makiyama, Norio Ureshino, Masahito Kotaka, Takayuki Shimose, Koji Ando, Hiroshi Saeki, Hideo Baba, Yoshihiko Maehara, Masaki Mori Cancer Chemother Pharmacol. 2020 Aug;86(2):285-294. doi: 10.1007/s00280-020-04108-x. Epub 2020 Jul 30.
29	RAD51 Expression as a Biomarker to Predict Efficacy of Preoperative Therapy and Survival for Esophageal Squamous Cell Carcinoma: A Large-cohort Observational Study (KSCC1307). Saeki H, Jogo T, Kawazoe T, Kamori T, Nakaji Y, Zaitsu Y, Fujiwara M, Baba Y, Nakamura T, Iwata N, Egashira A, Nakanoko T, Morita M, Tanaka Y, Kimura Y, Shibata T, Nakashima Y, Emi Y, Makiyama A, Oki E, Tokunaga S, Shimokawa M, Mori M; Kyushu Study Group of Clinical Cancer (KSCC). Ann Surg. 2020 May 29. doi: 10.1097/SLA.0000000000003975. Online ahead of print.
28	Multicenter Cohort Study to Assess the Association Between Changes on Imaging and Outcome After Regorafenib Treatment (KSCC1603) Eiji Oki, Masahiro Kawahira, Tetsuya Kusumoto, Satoshi Yuki, Kazuteru Hatanaka, Yoshimitsu Kobayashi, Akihiro Nishie, Satoshi Kawanami, Akitaka Makiyama, Hiroshi Saeki, Sanae Sakamoto, Yoshito Komatsu, Mototsugu Shimokawa, Masaki Mori, Taito Esaki Oncology. 2020 Jul 8;1-8. doi: 10.1159/000507814. Online ahead of print.
27	Efficacy and feasibility of S-1 plus oxaliplatin (C-SOX) for treating patients with stage III colon cancer (KSCC1303): final analysis of 3-year disease-free survival. Ando K, Emi Y, Miyanari N, Tsuji A, Sakai K, Sawai T, Imamura H, Mori S, Tokunaga S, Oki E, Saeki H, Kakeji Y, Akagi Y, Baba H, Maehara Y, Mori M; Kyushu Study Group of Clinical Cancer (KSCC). Int J Clin Oncol. 2020 Mar 18. doi: 10.1007/s10147-020-01646-5. [Epub ahead of print]
26	Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B. Yuki S, Shinozaki K, Kashiwada T, Kusumoto T, Iwatsuki M, Satake H, Kobayashi K, Esaki T, Nakashima Y, Kawanaka H, Emi Y, Komatsu Y, Shimokawa M, Makiyama A, Saeki H, Oki E, Baba H, Mori M. Cancer Chemother Pharmacol. 2020 Jan;85(1):217-223. doi: 10.1007/s00280-019-03991-3. Epub 2019 Nov 25.
25	Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-A) Shun Sasaki, Eiji Oki, Hiroshi Saeki, Takayuki Shimose, Sanae Sakamoto, Qingjiang Hu, Kensuke Kudo, Yasuo Tsuda, Yuichiro Nakashima, Koji Ando, Yoshito Akagi, Yoshihiro Kakeji, Hideo Baba, Yoshihiko Maehara Int J Clin Oncol. 2019 Oct;24(10):1204-1213. doi: 10.1007/s10147-019-01460-8. Epub 2019 May 6.
24	Comparison of computed tomography imaging analyses for evaluation after chemotherapy in patients with colorectal cancer: a retrospective pooled analysis of six phase II clinical trials. Hirose K, Oki E, Shimose T, Sakamoto S, Sasaki S, Jogo T, Hu Q, Tsuda Y, Ando K, Nakashima Y, Saeki H, Mori M. Int J Clin Oncol. 2019 Jul 22. doi: 10.1007/s10147-019-01509-8. [Epub ahead of print]
23	Pancreatic cancer arising from the remnant pancreas after pancreatectomy: a multicenter retrospective study by the Kyushu Study Group of Clinical Cancer. Hashimoto D, Arima K, Nakagawa S, Negoro Y, Hirata T, Hirota M, Inomata M, Fukuzawa K, Ohga T, Saeki H, Oki E, Yamashita YI, Chikamoto A, Baba H, Maehara Y. J Gastroenterol. 2018 Dec 4. doi: 10.1007/s00535-018-01535-9. [Epub ahead of print]
22	Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604). Saeki H, Oki E, Kashiwada T, Arigami T, Makiyama A, Iwatsuki M, Narita Y, Satake H, Matsuda Y, Sonoda H, Shimokawa M, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC). Eur J Cancer. 2018 Dec;105:41-49. doi: 10.1016/j.ejca.2018.09.024. Epub 2018 Nov 2.
21	Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402). Tanioka H, Miyamoto Y, Tsuji A, Asayama M, Shiraishi T, Yuki S, Kotaka M, Makiyama A, Shimokawa M, Shimose T, Masuda S, Yamaguchi T, Komatsu Y, Saeki H, Emi Y, Baba H, Oki E, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC). Oncology. 2018 Mar 7. doi: 10.1159/000486624. [Epub ahead of print]
20	Study protocol of a phase II clinical trial (KSCC1501A) examining oxaliplatin + S-1 for treatment of HER2-negative advanced/recurrent gastric cancer previously untreated with chemotherapy. Saeki H, Emi Y, Oki E, Tokunaga S, Kakeji Y, Akagi Y, Baba H, Baba E, Maehara Y; Kyushu Study group of Clinical Cancer (KSCC). BMC Cancer. 2018 Jan 8;18(1):57. doi: 10.1186/s12885-017-3937-6.
19	Low Visceral Fat Content Is a Negative Predictive Marker for Bevacizumab in Metastatic Colorectal Cancer. Miyamoto Y, Oki E, Emi Y, Tokunaga S, Shimokawa M, Ogata Y, Akagi Y, Sakamoto Y, Tanaka T, Saeki H, Maehara Y, Baba H Anticancer Res. 2018 Jan;38(1):491-499
18	A prospective study of XELIRI plus bevacizumab as a first-line therapy in Japanese patients with unresectable or recurrentcolorectal cancer (KSCC1101) Ando K, Emi Y, Suenaga T, Hamanoue M, Maekawa S, Sakamoto Y, Kai S, Satake H, Shimose T, Shimokawa M, Saeki H, Oki E, Sakai K, Akagi Y, Baba H, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC). Int J Clin Oncol. 2017 May 19. doi: 10.1007/s10147-017-1140-z. [Epub ahead of print]
17	Final report of KSCC0803: feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japan. Minami K, Morita M, Emi Y, Okamoto M, Tanaka E, Nagata S, Touyama T, Ohgaki K, Tanaka T, Okumura H, Suenaga T, Tokunaga S, Oki E, Kakeji Y, Akagi Y, Baba H, Natsugoe S, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC). Int J Clin Oncol. 2017 Jan 18. doi: 10.1007/s10147-017-1088-z. [Epub ahead of print]
16	Phase II trial of capecitabine plus modified cisplatin (mXP) as first-line therapy in Japanese patients with metastatic gastric cancer (KSCC1104). Satake H, Iwatsuki M, Uenosono Y, Shiraishi T, Tanioka H, Saeki H, Sugimachi K, Kitagawa D, Shimokawa M, Oki E, Emi Y, Kakeji Y, Tsuji A, Akagi Y, Natsugoe S, Baba H, Maehara Y; Kyushu Study Group of Clinical Cancer. Cancer Chemother Pharmacol. 2017 Jan;79(1):147-153. doi: 10.1007/s00280-016-3204-6.
15	Expression of the anaphylatoxin C5a receptor in gastric cancer: implications for vascular invasion and patient outcomes. Nitta H, Shimose T, Emi Y, Imamura T, Ohnishi K, Kusumoto T, Yamamoto M, Fukuzawa K, Takahashi I, Higashi H, Tsuji A, Akagi Y, Oki E, Maehara Y, Baba H; Kyushu Study Group of Clinical Cancer (KSCC) ancillary study. Med Oncol. 2016 Nov;33(11):118. doi: 10.1007/s12032-016-0834-9. Epub 2016 Sep 29.
14	Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study). Takahashi T, Emi Y, Oki E, Kobayashi K, Tsuji A, Shimokawa M, Tanaka T, Akagi Y, Ogata Y, Baba H, Yoshida K, Natsugoe S, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC). Cancer Chemother Pharmacol. 2016 Jul 28. [Epub ahead of print]
13	Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCC1302). Oki E, Tokunaga S, Emi Y, Kusumoto T, Yamamoto M, Fukuzawa K, Takahashi I, Ishigami S, Tsuji A, Higashi H, Nakamura T, Saeki H, Shirabe K, Kakeji Y, Sakai K, Baba H, Nishimaki T, Natsugoe S, Maehara Y; Kyushu Study Group of Clinical Cancer. Gastric Cancer. 2016 Jul;19(3):968-76. doi: 10.1007/s10120-015-0530-z. Epub 2015 Aug 11.
12	A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902). Ogata Y, Shimokawa M, Tanaka T, Emi Y, Oki E, Saeki H, Sadanaga N, Kusumoto T, Touyama T, Kimura M, Baba H, Akagi Y, Shirouzu K, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC). Int J Clin Oncol. 2016 Apr;21(2):335-43. doi: 10.1007/s10147-015-0895-3. Epub 2015 Sep 4.
11	Evaluation of resectability after neoadjuvant chemotherapy for primary non-resectable colorectal liver metastases: A multicenter study. Takatsuki M, Tokunaga S, Uchida S, Sakoda M, Shirabe K, Beppu T, Emi Y, Oki E, Ueno S, Eguchi S, Akagi Y, Ogata Y, Baba H, Natsugoe S, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC). Eur J Surg Oncol. 2016 Feb;42(2):184-9. doi: 10.1016/j.ejso.2015.11.007. Epub 2015 Nov 22.
10	Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801). Miwa K, Oki E, Emi Y, Saeki H, Kusumoto T, Akagi Y, Ogata Y, Samura H, Tokunaga S, Ishikawa H, Tanaka T, Sueyoshi S, Higashi H, Matsuda H, Touyama T, Maehara Y; Kyushu Study Group of Clinical Cancer. Int J Clin Oncol. 2016 Feb;21(1):110-7. doi: 10.1007/s10147-015-0850-3. Epub 2015 Jun 3.
9	S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102). Miyamoto Y, Tsuji A, Tanioka H, Maekawa S, Kawanaka H, Kitazono M, Oki E, Emi Y, Murakami H, Ogata Y, Saeki H, Shimokawa M, Natsugoe S, Akagi Y, Baba H, Maehara Y. Int J Clin Oncol. 2016 Jan 8. [Epub ahead of print]
8	Phase II Trial of S-1 and Oxaliplatin Plus Cetuximab for Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases (KSCC1002). Oki E, Emi Y, Miyamoto Y, Kabashima A, Higashi H, Ogata Y, Ikebe M, Saeki H, Tokunaga S, Shirabe K, Beppu T, Uchida S, Takatsuki M, Sakoda M, Eguchi S, Akagi Y, Kakeji Y, Baba H, Natsugoe S, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC). Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1067-74. doi: 10.1245/s10434-015-4771-1. Epub 2015 Sep 3.
7	Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab (KSCC0802 Study). Beppu T, Emi Y, Tokunaga S, Oki E, Shirabe K, Ueno S, Kuramoto M, Kabashima A, Takahashi I, Samura H, Eguchi S, Akagi Y, Natsugoe S, Ogata Y, Kakeji Y, Baba H, Maehara Y; Kyushu Study group of Clinical Cancer (KSCC). Anticancer Res. 2014 Nov;34(11):6655-62.
6	Impact of second-line and later cetuximab-containing therapy and KRAS genotypes in patients with metastatic colorectal cancer: a multicenter study in Japan. Saeki H, Emi Y, Kumashiro R, Otsu H, Kawano H, Ando K, Ida S, Kimura Y, Tokunaga E, Oki E, Morita M, Shimokawa M, Maehara Y. Surg Today. 2014 Aug;44(8):1457-64. doi: 10.1007/s00595-013-0716-0. Epub 2013 Sep 8.
5	Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome. Imai K, Emi Y, Iyama KI, Beppu T, Ogata Y, Kakeji Y, Samura H, Oki E, Akagi Y, Maehara Y, Baba H; Kyusyu Study Group of Clinical Cancer (KSCC) ancillary study. Eur J Surg Oncol. 2014 May;40(5):559-66. doi: 10.1016/j.ejso.2013.12.009. Epub 2013 Dec 20.
4	Phase II trial of alternating mFOLFOX6 and FOLFIRI regimens in the first-line treatment for unresectable or metastatic colorectal cancer (KSCC0701). Oki E, Emi Y, Akagi Y, Tokunaga S, Sadanaga N, Tanaka T, Ogata Y, Saeki H, Kakeji Y, Baba H, Nishimaki T, Natsugoe S, Shirouzu K, Maehara Y; Kyushu Study Group of Clinical Cancer. Oncology. 2013;84(4):233-9. doi: 10.1159/000346690. Epub 2013 Jan 31.
3	Initial report of KSCC0803: feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japanese patients. Emi Y, Kakeji Y, Oki E, Saeki H, Ando K, Kitazono M, Sakaguchi Y, Morita M, Samura H, Ogata Y, Akagi Y, Natsugoe S, Shirouzu K, Tokunaga S, Sirzen F, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC). Int J Clin Oncol. 2013 Apr;18(2):254-9. doi: 10.1007/s10147-011-0371-7. Epub 2012 Jan 13.
2	A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as second-line treatment for advanced colorectal cancer: a Japanese experience. Ogata Y, Tokunaga S, Emi Y, Oki E, Saeki H, Shirabe K, Hasegawa H, Sadanaga N, Samura H, Fujita F, Tanaka T, Kitazono M, Yamamoto M, Morikita T, Inomata M, Kakeji Y, Shirouzu K, Maehara Y; Kyushu Study Group of Clinical Cancer. Surg Today. 2011 Jan;41(1):84-90. doi: 10.1007/s00595-010-4418-6. Epub 2010 Dec 30.
1	A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as first-line treatment for advanced colorectal cancer: a Japanese experience. Baba H, Hayashi N, Emi Y, Kakeji Y, Egashira A, Oki E, Shirabe K, Toyama T, Ohga T, Yamamoto M, Hasegawa H, Kohakura F, Higashi H, Niwa K, Fujita F, Ogata Y, Kohnoe S, Inomata M, Samura H, Tokunaga S, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC). Surg Today. 2011 Dec;41(12):1610-6. doi: 10.1007/s00595-011-4589-9. Epub 2011 Oct 4.